24 Months of Exemestane or Letrozole to Treat Breast Cancer
This research study is looking at certain medications used to treat breast cancer called aromatase inhibitors.
This study is being done because it has been determined that an aromatase inhibitor is the best way to treat certain types of breast cancer. The effects of exemestane and letrozole, both are aromatase inhibitors with very different chemical compounds, will be studied to try to identify which women are more likely to have certain benefits or side effects from one or the other of these two medications. The researchers will be looking at the women's genes and at the medication's effects on their body.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism|
- Identify which women are more likely to have certain benefits or side effects from one or the other of exemestane and letrozole. The researchers will be looking at their genes and at the medication's effects on their body. [ Time Frame: refer to protocol ] [ Designated as safety issue: No ]
|Study Start Date:||November 2005|
|Estimated Study Completion Date:||November 2015|
|Estimated Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
Drug: Exemestane and letrozole
|United States, Michigan|
|University of Michigan|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Daniel Hayes, M.D.||University of Michigan|